首页> 外文期刊>Neurobiology of disease >Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism
【24h】

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

机译:Sirtuin 3通过在帕金森主义的病毒表达突变体α-突触核蛋白大鼠模型中稳定线粒体生物渗透物来拯救神经元

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Parkinson's disease (PD) is a neurodegenerative movement disorder, which affects approximately 1–2% of the population over 60 years of age. Current treatments for PD are symptomatic, and the pathology of the disease continues to progresses over time until palliative care is required. Mitochondria are key players in the pathology of PD. Genetic and post mortem studies have shown a large number of mitochondrial abnormalities in the substantia nigra pars compacta (SNc) of the parkinsonian brain. Furthermore, physiologically, mitochondria of nigral neurons are constantly under unusually high levels of metabolic stress because of the excitatory properties and architecture of these neurons. The protein deacetylase, Sirtuin 3 (SIRT3) reduces the impact subcellular stresses on mitochondria, by stabilising the electron transport chain (ETC), and reducing oxidative stress. We hypothesised that viral overexpression of myc-tagged SIRT3 (SIRT3-myc) would slow the progression of PD pathology, by enhancing the functional capacity of mitochondria. For this study, SIRT3-myc was administered both before and after viral induction of parkinsonism with the AAV-expressing mutant (A53T) α-synuclein. SIRT3-myc corrected behavioural abnormalities, as well as changes in striatal dopamine turnover. SIRT3-myc also prevented degeneration of dopaminergic neurons in the SNc. These effects were apparent, even when SIRT3-myc was transduced after the induction of parkinsonism, at a time point when cell stress and behavioural abnormalities are already observed. Furthermore, in an isolated mitochondria nigral homogenate prepared from parkinsonian SIRT3–myc infected animals, SIRT3 targeted the mitochondria, to reduce protein acetylation levels. Our results demonstrate that transduction of SIRT3 has the potential to be an effective disease-modifying strategy for patients with PD. This study also provides potential mechanisms for the protective effects of SIRT3-myc.
机译:摘要帕金森病(PD)是一种神经变性运动障碍,影响大约1-2%的人口超过60岁。目前对PD的治疗是对症性的,并且随着时间的推移,疾病的病理仍在继续,直到需要姑息治疗。线粒体是PD病理学的关键球员。遗传和后验尸研究表明了Parkinsonian大脑的基础NIGRA Compara(SNC)的大量线粒体异常。此外,由于这些神经元的兴奋性和结构,生理学上,Nigral神经元的线粒体持续在异常高水平的代谢应力下。通过稳定电子传递链(ETC)并降低氧化应激,蛋白质脱乙酰酶,Sirtuin 3(Sirt3)降低线粒体上的凋落亚细胞应力。我们假设Myc标记的SIRT3(SIRT3-MYC)的病毒过度表达将通过提高线粒体的功能能力来减缓PD病理学的进展。对于本研究,SIRT3-MYC在帕金森主义的病毒诱导之前和之后施用与AAV表达突变体(A53T)α-突触核蛋白。 SIRT3-MYC纠正了行为异常,以及纹状体多巴胺营业额的变化。 SIRT3-MYC还防止了SNC中多巴胺能神经元的退化。这些效果显而易见,即使在诱导帕金森主义之后转导的时,在已经观察到细胞应力和行为异常的时间点。此外,在由Parkinsonian Sirt3-Myc受感染的动物制备的孤立的线粒体髂骨素中,SIRT3靶向线粒体,以降低蛋白质乙酰化水平。我们的结果表明,SIRT3的转导具有PD患者的有效疾病改性策略。本研究还提供了SIRT3-MYC的保护作用的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号